These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 33634341)

  • 1. New pharmacotherapy options for noninfectious posterior uveitis.
    Pleyer U; Neri P; Deuter C
    Int Ophthalmol; 2021 Jun; 41(6):2265-2281. PubMed ID: 33634341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New pharmacotherapy options for noninfectious posterior uveitis.
    Pleyer U; Stübiger N
    Expert Opin Biol Ther; 2014 Dec; 14(12):1783-99. PubMed ID: 25243865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging drugs for the treatment of noninfectious uveitis.
    Pleyer U; Pohlmann D; Kardeş E; Poddubnyy D; Rademacher J
    Expert Opin Emerg Drugs; 2019 Sep; 24(3):173-190. PubMed ID: 31498689
    [No Abstract]   [Full Text] [Related]  

  • 4. A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults.
    Squires H; Poku E; Bermejo I; Cooper K; Stevens J; Hamilton J; Wong R; Denniston A; Pearce I; Quhill F
    Health Technol Assess; 2017 Nov; 21(68):1-170. PubMed ID: 29183563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis: Evolution through Preclinical and Clinical Studies.
    Nguyen QD; Merrill PT; Sepah YJ; Ibrahim MA; Banker A; Leonardi A; Chernock M; Mudumba S; Do DV
    Ophthalmology; 2018 Dec; 125(12):1984-1993. PubMed ID: 30060978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III.
    Suhler EB; Adán A; Brézin AP; Fortin E; Goto H; Jaffe GJ; Kaburaki T; Kramer M; Lim LL; Muccioli C; Nguyen QD; Van Calster J; Cimino L; Kron M; Song AP; Liu J; Pathai S; Camez A; Schlaen A; van Velthoven MEJ; Vitale AT; Zierhut M; Tari S; Dick AD
    Ophthalmology; 2018 Jul; 125(7):1075-1087. PubMed ID: 29429764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.
    Sheppard J; Joshi A; Betts KA; Hudgens S; Tari S; Chen N; Skup M; Dick AD
    JAMA Ophthalmol; 2017 Jun; 135(6):511-518. PubMed ID: 28426849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results.
    Jaffe GJ; Lin P; Keenan RT; Ashton P; Skalak C; Stinnett SS
    Ophthalmology; 2016 Sep; 123(9):1940-8. PubMed ID: 27421623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonsteroidal drugs for the treatment of noninfectious posterior and intermediate uveitis.
    Imrie FR; Dick AD
    Curr Opin Ophthalmol; 2007 May; 18(3):212-9. PubMed ID: 17435428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.
    ; Kempen JH; Altaweel MM; Drye LT; Holbrook JT; Jabs DA; Sugar EA; Thorne JE
    Ophthalmology; 2015 Oct; 122(10):1967-75. PubMed ID: 26298715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial.
    ; Kempen JH; Altaweel MM; Holbrook JT; Jabs DA; Louis TA; Sugar EA; Thorne JE
    Ophthalmology; 2011 Oct; 118(10):1916-26. PubMed ID: 21840602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexamethasone for ocular inflammation.
    Saraiya NV; Goldstein DA
    Expert Opin Pharmacother; 2011 May; 12(7):1127-31. PubMed ID: 21457057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corticosteroid implants for chronic non-infectious uveitis.
    Reddy A; Liu SH; Brady CJ; Sieving PC; Palestine AG
    Cochrane Database Syst Rev; 2023 Jan; 1(1):CD010469. PubMed ID: 36645716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
    Suhler EB; Jaffe GJ; Fortin E; Lim LL; Merrill PT; Dick AD; Brezin AP; Nguyen QD; Thorne JE; Van Calster J; Cimino L; Adan A; Goto H; Kaburaki T; Kramer M; Vitale AT; Kron M; Song AP; Liu J; Pathai S; Douglas KM; Schlaen A; Muccioli C; Van Velthoven MEJ; Zierhut M; Rosenbaum JT
    Ophthalmology; 2021 Jun; 128(6):899-909. PubMed ID: 33157077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program.
    Merrill PT; Clark WL; Banker AS; Fardeau C; Franco P; LeHoang P; Ohno S; Rathinam SR; Ali Y; Mudumba S; Shams N; Nguyen QD;
    Ophthalmology; 2020 Oct; 127(10):1405-1415. PubMed ID: 32564920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis.
    Lowder C; Belfort R; Lightman S; Foster CS; Robinson MR; Schiffman RM; Li XY; Cui H; Whitcup SM;
    Arch Ophthalmol; 2011 May; 129(5):545-53. PubMed ID: 21220619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behçet's disease uveitis: is there a need for new emerging drugs?
    Tugal-Tutkun I; Çakar Özdal P
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):531-547. PubMed ID: 33147420
    [No Abstract]   [Full Text] [Related]  

  • 18. Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage. Proceedings of an expert panel roundtable discussion.
    Nguyen QD; Callanan D; Dugel P; Godfrey DG; Goldstein DA; Wilensky JT
    Retina; 2006 Oct; Suppl():1-16. PubMed ID: 17050954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Sarilumab for the Treatment of Posterior Segment Noninfectious Uveitis (SARIL-NIU):: The Phase 2 SATURN Study.
    Heissigerová J; Callanan D; de Smet MD; Srivastava SK; Karkanová M; Garcia-Garcia O; Kadayifcilar S; Ozyazgan Y; Vitti R; Erickson K; Athanikar A; Chu K; Saroj N; Sundaram PA; Varona R; Corp-Dit-Genti V; Buggage R; Cheng Y; Soo Y; Nguyen QD
    Ophthalmology; 2019 Mar; 126(3):428-437. PubMed ID: 30316888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of an Injectable Fluocinolone Acetonide Insert on Recurrence Rates in Chronic Noninfectious Uveitis Affecting the Posterior Segment: Twelve-Month Results.
    Jaffe GJ; Foster CS; Pavesio CE; Paggiarino DA; Riedel GE
    Ophthalmology; 2019 Apr; 126(4):601-610. PubMed ID: 30367884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.